semaglutide and flonase vs. Other GLP-1 Receptor Agonists and metabolic wellness. Chinese biotech aims to finish

Mollema ED, Snoek FJ, Pouwer F, Heine RJ, van der Ploeg HM

As obesity becomes more firmly recognized as a chronic metabolic disease, the gap between diabetes and weight loss treatment pathways may narrow

Clinical trials have shown compelling results, with patients losing between 14.9% to 17.4% of their original body weight over 68 weeksan achievement significantly beyond what diet and exercise typically offer

The medication changes what you eat and how much, but it does not automatically change the thoughts and habits that sit behind those behaviours

Patients had a greater tendency to stick to semaglutide therapy

They are only legally sold and distributed for research purposes